12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ryzodeg insulin degludec/insulin aspart regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-4 that Novo Nordisk provided sufficient safety and efficacy data to support approval of 2 products for Type I and II diabetes. The products were Tresiba insulin Degludec, a long-acting insulin analog, and Ryzodeg, a combination of 70% insulin Degludec and 30% Novo Nordisk's NovoLog insulin aspart. Panel members were concerned about the cardiovascular risks of the 2 therapeutics, but felt the...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >